A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Saved in:
| Title: | A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. |
|---|---|
| Authors: | Yardley DA; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN. Electronic address: dyardley@tnonc.com., Liggett W; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN., Mainwaring M; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN., Castrellon A; Memorial Cancer Institute, Hollywood, FL., Blakely L; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN., Hemphill B; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN., Anz B 3rd; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN., Young RR; The Center for Cancer and Blood Disorders, Fort Worth, TX., Shastry M; Sarah Cannon Research Institute, Nashville, TN., DeBusk LM; Sarah Cannon Research Institute, Nashville, TN., Hainsworth JD; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN., Burris HA 3rd; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN. |
| Source: | Clinical breast cancer [Clin Breast Cancer] 2020 Apr; Vol. 20 (2), pp. 89-97. Date of Electronic Publication: 2019 Jun 26. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 31932237 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Yardley+DA%22">Yardley DA</searchLink>; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN. Electronic address: dyardley@tnonc.com.<br /><searchLink fieldCode="AU" term="%22Liggett+W%22">Liggett W</searchLink>; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22Mainwaring+M%22">Mainwaring M</searchLink>; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22Castrellon+A%22">Castrellon A</searchLink>; Memorial Cancer Institute, Hollywood, FL.<br /><searchLink fieldCode="AU" term="%22Blakely+L%22">Blakely L</searchLink>; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22Hemphill+B%22">Hemphill B</searchLink>; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22Anz+B+3rd%22">Anz B 3rd</searchLink>; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22Young+RR%22">Young RR</searchLink>; The Center for Cancer and Blood Disorders, Fort Worth, TX.<br /><searchLink fieldCode="AU" term="%22Shastry+M%22">Shastry M</searchLink>; Sarah Cannon Research Institute, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22DeBusk+LM%22">DeBusk LM</searchLink>; Sarah Cannon Research Institute, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22Hainsworth+JD%22">Hainsworth JD</searchLink>; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22Burris+HA+3rd%22">Burris HA 3rd</searchLink>; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100898731%22">Clinical breast cancer</searchLink> [Clin Breast Cancer] 2020 Apr; Vol. 20 (2), pp. 89-97. <i>Date of Electronic Publication: </i>2019 Jun 26. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>100898731 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1938-0666 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215268209%22">15268209 </searchLink><i>NLM ISO Abbreviation: </i>Clin Breast Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31932237 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.clbc.2019.06.005 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 89 Titles: – TitleFull: A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Yardley DA – PersonEntity: Name: NameFull: Liggett W – PersonEntity: Name: NameFull: Mainwaring M – PersonEntity: Name: NameFull: Castrellon A – PersonEntity: Name: NameFull: Blakely L – PersonEntity: Name: NameFull: Hemphill B – PersonEntity: Name: NameFull: Anz B 3rd – PersonEntity: Name: NameFull: Young RR – PersonEntity: Name: NameFull: Shastry M – PersonEntity: Name: NameFull: DeBusk LM – PersonEntity: Name: NameFull: Hainsworth JD – PersonEntity: Name: NameFull: Burris HA 3rd IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2020 Apr Type: published Y: 2020 Identifiers: – Type: issn-electronic Value: 1938-0666 Numbering: – Type: volume Value: 20 – Type: issue Value: 2 Titles: – TitleFull: Clinical breast cancer Type: main |
| ResultId | 1 |
